Blue Jet Healthcare has successfully closed its Qualified Institutions Placement (QIP), allotting 15,810,276 equity shares at an issue price of ₹506.00 per share, aggregating ₹8000.00 million. The allotment includes a premium of ₹504.00 per share over the face value of ₹2, incorporating a discount of ₹25.70, or 4.83%, to the floor price of ₹531.70. The Investment and Finance Committee approved the closure and final allocation during a meeting held on July 9, 2026.

QIP Allocation Details

The committee approved the allocation of shares to eligible qualified institutional buyers upon receipt of application forms and funds in the escrow accounts. The issue price was determined in consultation with the book running lead managers, utilizing the maximum permissible discount under the regulations.

Pursuant to the allotment, the paid-up equity share capital of the company has increased from ₹346,930,850 consisting of 173,465,425 equity shares of ₹2 each to ₹378,551,402 consisting of 189,275,701 equity shares of ₹2 each.

Major Allottees

Shamyak Investment Private Limited emerged as the largest subscriber, receiving 5,434,785 shares, which represents 34.38% of the total issue size. The shareholding pattern of the company, before and after the issue, will be submitted along with the listing application.

Regulatory Framework and Approvals

The placement follows the pricing formula prescribed under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The issue was authorized by a special resolution passed by shareholders on June 17, 2026, and an initial Board approval on May 25, 2026. The committee meeting on July 9, 2026, commenced at 10:10 pm and concluded at 10:25 pm. The filing was submitted to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Blue Jet Healthcare Limited reported an 18.8% decline in net profit to ₹2,478.16 million for the financial year ended March 31, 2026, compared to ₹3,052.03 million in the previous year. Revenue from operations decreased 7.9% to ₹9,423.67 million from ₹10,247.29 million in FY25, primarily driven by lower sales across its product segments including Contrast Media Intermediate and Artificial Sweeteners. The company’s total income stood at ₹10,110.15 million for the year.

The Board of Directors approved the audited standalone financial statements at its meeting held on May 25, 2026. The company has proposed a final dividend of ₹1.20 per equity share for the financial year 2025-26, amounting to ₹208.16 million, which is subject to the approval of shareholders at the ensuing Annual General Meeting. A final dividend of ₹1.20 per share for the previous year was declared and paid during the current year.

Financial Performance

The company’s earnings per share (EPS) for the year stood at ₹14.29, down from ₹17.59 in the previous year. Total expenses for FY26 increased marginally to ₹6,701.41 million from ₹6,670.14 million in the prior year. The cost of materials consumed decreased to ₹3,881.23 million from ₹5,402.45 million, while employee benefits expense rose to ₹735.35 million from ₹609.97 million.

Finance costs for the year rose significantly to ₹62.39 million compared to ₹0.98 million in the previous year, primarily due to interest on lease liabilities. Depreciation and amortisation expenses increased to ₹240.02 million from ₹177.89 million.

Operational Highlights

Blue Jet Healthcare’s cash and cash equivalents as of March 31, 2026, stood at ₹608.57 million, up from ₹329.79 million at the end of the previous year. The company generated net cash of ₹3,341.46 million from operating activities. However, net cash used in investing activities was ₹2,755.78 million, largely attributed to the purchase of investments amounting to ₹3,040.01 million.

The auditor, KKC & Associates LLP, highlighted revenue recognition as a key audit matter, noting that revenue is recognised at a point in time when control is transferred, generally coinciding with agreed customer terms. The audit report also noted that the company used accounting software operated by a third-party service provider for payroll records, for which the auditor was unable to comment on the audit trail feature's operation. Additionally, inventory records were maintained manually in spreadsheets until December 7, 2025, which lacked an audit trail feature.

The audited financial statements are subject to adoption by the shareholders at the ensuing Annual General Meeting.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0KBH01020/0c653189633c4045.pdf